-
SAExploration Holdings, Inc. (NASDAQ: SAEX)
shares dipped 45.7 percent to $17.90. SAExploration shares have dropped 92.92 percent over the past 52 weeks, while the S&P
500 index has gained 3.74 percent in the same period.
-
Check Cap Ltd (NASDAQ: CHEK) shares tumbled 24.6
percent to $2.29 after the company reported a $5.9 million financing.
-
Ceragon Networks Ltd (NASDAQ: CRNT) fell 12.7
percent to $2.00 following Q2 results. Ceragon Networks reported Q2 profit of $49,000 on revenue of $70 million
-
Epizyme Inc (NASDAQ: EPZM) shares declined 12
percent to $9.09. Epizyme reported a narrower-than-expected quarterly loss, but sales missed analysts’ expectations.
-
Research Frontiers, Inc. (NASDAQ: REFR) shares
declined 11.8 percent to $2.84. On Thursday, Research Frontiers reported a Q2 loss of $0.10 per share.
-
Atara Biotherapeutics Inc (NASDAQ: ATRA) shares
dropped 10.8 percent to $22.19 following Q2 results. Atara Bio reported a Q2 loss of $0.66 per share.
-
Hyster-Yale Materials Handling Inc (NYSE: HY) fell
10.2 percent to $59.00 as the company posted downbeat quarterly earnings.
-
Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP)
shares declined 10 percent to $7.84 after the company reported weak Q2 results.
-
Digital Ally, Inc. (NASDAQ: DGLY) fell 9.5
percent to $5.14. Digital Ally reported a Q2 adjusted loss of $0.45 per share on revenue of $4.4 million.
-
TG Therapeutics Inc (NASDAQ: TGTX) declined 8.1
percent to $5.53 after the company reported a wider-than-expected Q2 loss.
-
Novo Nordisk A/S (ADR) (NYSE: NVO) shares dropped
4.6 percent to $47.59. Bank of America downgraded Novo-Nordisk from Buy to Neutral.
-
Dean Foods Co (NYSE: DF) shares dropped 3 percent to
$18.27 after the company reported weaker-than-expected quarterly earnings.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.